Resumen de Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram
Ana Fernández Montes, Francisca Vázquez Rivera, Nieves Martínez Lago, M. Covela, A. Cousillas Castiñeiras, Paula González Villarroel, Juan de la Cámara Gómez, J. C. Méndez Méndez, Mercedes Salgado Fernández, Sonia Candamio Folgar, Margarita Reboredo López, Marta Carmona Campos, Elena Gallardo Martín, Mónica Jorge Fernández, Mari Luz Pellón Augusto, L. París Bouzas, Jesús García Gómez
Introduction Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain.
Patients and methods This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies.
Results A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/µl, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml.
Conclusion The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.
